Dr. Kevan Shokat is an Investigator of the Howard Hughes Medical Institute, Professor in the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco and Professor in the Department of Chemistry at the University of California, Berkeley. Dr. Shokat’s research group is focused on the discovery of new small molecule tools and drug candidates targeting protein/lipid kinases, GTPases and RNA helicases. His laboratory utilizes the tools of synthetic organic chemistry, protein engineering, structural biology, biochemistry and cell biology. He was inducted into the National Academy of Sciences (2010), the National Academy of Medicine (2011) and the American Academy of Arts and Sciences (2011). He has commercialized discoveries from his laboratory through co-founding several biotechnology companies, including Intellikine, Araxes, Wellspring Biosciences, Kura Oncology, eFFECTOR Therapeutics, Mitokinin, Revolution Medicines and Kumquat Biosciences. He received his B.A. in chemistry from Reed College and Ph.D. in organic chemistry at University of California, Berkeley with Professor Peter Schultz, and he carried out post-doctoral work in cellular immunology at Stanford University with Professor Chris Goodnow.